Landing
Macula Society (MS) 2024
Pegcetacoplan vs Avacincaptad Pegol in Geographic Atrophy: An Anchored Matching-Adjusted Indirect Comparison of Three Phase 3 Trials
Long-Term Efficacy and Safety of Pegcetacoplan Over 36 Months: Results From 12 Months of the GALE Open-Label Extension Study
Pegcetacoplan Delays Time to Loss of Central Macular Sensitivity: A Microperimetry Analysis of the Phase 3 OAKS Study
The Photoreceptor/Retinal Pigment Epithelium Integrity Loss (PR/RPE Ratio) in Geographic Atrophy Secondary to AMD Is a Significant Predictor for Disease Activity and Therapeutic Response
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.